Phase 2 Study of YS110, a Recombinant Humanized Anti-CD26 Monoclonal Antibody, in Japanese Patients With Advanced Malignant Pleural Mesothelioma

Phase 2 Study of YS110, a Recombinant Humanized Anti-CD26 Monoclonal Antibody, in Japanese Patients With Advanced Malignant Pleural Mesothelioma

Introduction: YS110, a humanized monoclonal antibody with a high affinity to CD26, exhibited promising antitumor activity and was generally well-tolerated in the phase 1 part of a phase 1 and 2 Japanese trial in patients with malignant pleural mesothelioma (MPM). Here we report the results of the ph...

Full description

Bibliographic Details
Main Authors: Kazuhiko Nakagawa, MD, PhD, Takashi Kijima, MD, PhD, Morihito Okada, MD, PhD, Masahiro Morise, MD, PhD, Motoyasu Kato, MD, PhD, Katsuya Hirano, MD, Nobukazu Fujimoto, MD, PhD, Mitsuhiro Takenoyama, MD, PhD, Hiroshi Yokouchi, MD, PhD, Yuichiro Ohe, MD, PhD, Toyoaki Hida, MD, PhD, Keisuke Aoe, MD, PhD, Takumi Kishimoto, MD, PhD, Masato Hirokawa, MSc, Hironori Matsuki, MEng, Yutaro Kaneko, BSc, Taketo Yamada, MD, PhD, Chikao Morimoto, MD, PhD, Masayuki Takeda, MD, PhD
Format: Article
Language:English
Published: Elsevier 2021-06-01
Series:JTO Clinical and Research Reports
Subjects:
YS110
Malignant mesothelioma
Phase 2
CD26
Japanese
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364321000370

Similar Items

Similar Items